Skip to main content

Susan Kay Murphy, PhD

Property title
Associate Professor in Obstetrics and Gynecology
Campus Mail: 226 B Wing LSRC, 450 Research Drive, Durham, NC 27708
Phone: (919) 681-3423
Email: susan.murphy@duke.edu

Ovarian and cervical cancer epigenetics, imprinted genes in ovarian and cervical cancers, identification of methylation biomarkers of disease, ovarian cancer stem cells, chemotherapeutic response in ovarian cancer, tumor dormancy, the influence of the in utero environment on DNA methylation and risk of disease.

Education and Training

  • Ph.D., Wake Forest University, 1998
  • B.A., University of North Carolina at Charlotte, 1992

Selected Grants and Awards

Publications

Resnick, KE, Alder, H, Secord, AA, Whitaker, R, Richardson, DL, Heaphy, C, Murphy, SK, Baba, T, Croce, C, and Colin, DE. "MiRNA patterns in ovarian cancer cell lines: Correlation with serum studies." GYNECOLOGIC ONCOLOGY 112, no. 2 (February 2009): S115-S116.

Scholars@Duke

Barnett, JC, Whitaker, R, Kondoh, E, Baba, T, Murphy, SK, and Berchuck, A. "Ovarian cancer tumor-infiltrating regulatory T cells are associated with a metastatic phenotype." GYNECOLOGIC ONCOLOGY 112, no. 2 (February 2009): S11-S11.

Scholars@Duke

Barnett, JC, Iverson, E, Dressman, H, Whitaker, R, Murphy, SK, Lancaster, J, and Berchuck, A. "Validation of the MAL gene as a predictor of survival in advanced-stage high-grade serous ovarian cancer." GYNECOLOGIC ONCOLOGY 112, no. 2 (February 2009): S123-S124.

Scholars@Duke

Baba, T, Convery, PA, Matsumura, N, Whitaker, RS, Kondoh, E, Perry, T, Huang, Z, Bentley, RC, Mori, S, Fujii, S, Marks, JR, Berchuck, A, and Murphy, SK. "Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells." Oncogene 28, no. 2 (January 15, 2009): 209-218.

Full Text

Lee, PS, Teaberry, V, Bland, AE, Huang, Z, Secord, AA, Berchuck, A, and Murphy, SK. "MAL, a gene associated with survival in epithelial ovarian cancer, is epigenetically regulated." March 2008.

Scholars@Duke

Matsumura, N, Huang, Z, Perry, T, Kroyer, D, Baba, T, Mori, S, Fujii, S, Berchuck, A, and Murphy, SK. "Methylation in ovarian cancer is related to poor prognosis and suppression of the transforming growth factor signaling pathway." GYNECOLOGIC ONCOLOGY 108, no. 3 (March 2008): S104-S104.

Scholars@Duke

Bernardini, MQ, Lee, P, Baba, T, Whitaker, RS, Murphy, SK, and Berchuck, A. "Microarray analysis defines patterns of gene expression associated with mutation of TP53 in ovarian cancer." GYNECOLOGIC ONCOLOGY 108, no. 3 (March 2008): S84-S84.

Scholars@Duke

Baba, T, Mori, S, Matsumura, N, Bernardini, M, Fujii, S, Berchuck, A, and Murphy, SK. "Microarray analysis identifies NSC668814 as a potentially active chemotherapeutic agent for platinum-resistant ovarian cancers with TP53 mutations." GYNECOLOGIC ONCOLOGY 108, no. 3 (March 2008): S72-S72.

Scholars@Duke

Baba, T, Convery, PA, Matsumura, N, Whitaker, RS, Perry, T, Huang, Z, Mori, S, Kondoh, E, Bentley, RC, Fujii, S, Marks, JR, Berchuck, A, and Murphy, SK. "Stem cell marker CD133 (PROMININ-1) is epigenetically regulated in ovarian cancer." March 2008.

Scholars@Duke

Kondoh, E, Baba, T, Matsurnura, N, Fujii, S, Berchuck, A, and Murphy, SK. "Targeting dormant ovarian cancer cells." GYNECOLOGIC ONCOLOGY 108, no. 3 (March 2008): S13-S14.

Scholars@Duke

Pages